Puducherry, India

Vijayan Sambasivam

This inventor holds 1 USPTO granted patent. Top assignee: Johns Hopkins University. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vijayan Sambasivam. Retrieved from https://idiyas.com/inventor/vijayan-sambasivam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Vijayan Sambasivam

Introduction

Vijayan Sambasivam is a notable inventor based in Puducherry, India. He has made significant contributions to the field of cancer treatment through his innovative research and patent.

Latest Patents

Sambasivam holds a patent for a method of treating or preventing cancer. This method involves administering a first agent that depletes regulatory T cells (Tregs) in a subject, followed by a second agent that comprises a checkpoint inhibitor. This innovative approach aims to enhance the effectiveness of cancer therapies.

Career Highlights

Vijayan Sambasivam is affiliated with The Johns Hopkins University, where he conducts his research. His work focuses on developing novel strategies for cancer treatment, showcasing his commitment to advancing medical science.

Collaborations

Some of his notable coworkers include William R. Bishai and John R. Murphy. Their collaboration contributes to the innovative research environment at The Johns Hopkins University.

Conclusion

Vijayan Sambasivam's work in cancer treatment exemplifies the impact of innovative research in medicine. His contributions are paving the way for new therapeutic strategies that could benefit many patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…